Easton Pharmaceuticals (Easton Pharmaceuticals) EV-to-EBIT : 0.00 (As of Jun. 19, 2024)

View and export this data going back to . Start your Free Trial

What is Easton Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Easton Pharmaceuticals's Enterprise Value is $0.00 Mil. Easton Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2021 was $-0.26 Mil. Therefore, Easton Pharmaceuticals's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for Easton Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

EAPH's EV-to-EBIT is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 17.12
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Easton Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2021 was $2.97 Mil. Easton Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2021 was $-0.26 Mil. Easton Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2021 was -8.78%.

Easton Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Easton Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Easton Pharmaceuticals EV-to-EBIT Chart

Easton Pharmaceuticals Annual Data

Trend

Dec01

Dec02

Dec03

Dec04

Dec18

Dec19

Dec20

EV-to-EBIT

Get a 7-Day Free Trial

-4.83

-2.50

-114.71

-17.40

Easton Pharmaceuticals Quarterly Data
	Jun02	Sep02	Dec02	Mar03	Jun03	Sep03	Dec03	Mar04	Jun04	Sep04	Dec04	Mar05	Jun05	Sep05	Dec18	Dec19	Dec20	Mar21	Jun21	Sep21
EV-to-EBIT	Get a 7-Day Free Trial															-	-17.40	-60.31	-17.87	-11.39

Competitive Comparison of Easton Pharmaceuticals's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Easton Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Easton Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Easton Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Easton Pharmaceuticals's EV-to-EBIT falls into.

Easton Pharmaceuticals EV-to-EBIT Calculation

Easton Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	0.000	/	-0.261
	=	0.00

Easton Pharmaceuticals's current Enterprise Value is $0.00 Mil.
Easton Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.26 Mil.

Easton Pharmaceuticals (OTCPK:EAPH) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Easton Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2021 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2021 )	=	EBIT	/	Enterprise Value (Q: Sep. 2021 )
	=	-0.261	/	2.971493
	=	-8.78 %

Easton Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2021 was $2.97 Mil.
Easton Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.26 Mil.

Easton Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Easton Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Easton Pharmaceuticals (Easton Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Easton Pharmaceuticals Inc (OTCPK:EAPH) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Bloor Street East, Suite 3500, Toronto, ON, CAN, M4W 1A8

Website

http://www.eastonpharmaceuticalsinc.com

Easton Pharmaceuticals Inc is a diversified specialty pharmaceutical company. It owns and develops proprietary transdermal delivery technology and therapeutic over the counter products and drugs to treat cancer and other diseases. The company also owns exclusive distribution rights in Mexico and Latin America for patented women's diagnostic and preventative care products. It is focused on the development of product Viorra. The firm's products include Nauseasol, Skin Renou HA, Kenestrin gel, and XILIVE, among others.